Michael Egholm is President & BioPharmaceuticals at PALL CORP (PLL). They have made 8 open-market trades across 2 companies since 2013, most recently 2026-08-20.
CIK 0001559779
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LAB | SELL | 2025-05-23 | 2025-05-28 | $0.94 | $5K | -0.9% | +9.2% | +18.3% |
| LAB | SELL | 2025-05-22 | 2025-05-27 | $1.00 | $5K | +3.9% | +24.5% | +21.6% |
| LAB | SELL | 2025-05-21 | 2025-05-22 | $1.03 | $5K | +11.3% | +26.8% | +26.8% |
| PLL | SELL | 2015-06-29 | 2015-06-30 | $124.55 | $1.9M | -25.0% | -1.8% | -1.8% |
| PLL | SELL | 2014-12-22 | 2014-12-23 | $100.40 | $762K | -25.0% | -1.8% | -1.8% |
| PLL | SELL | 2014-07-14 | 2014-07-16 | $82.03 | $211K | -25.0% | -1.8% | -1.8% |
| PLL | SELL | 2013-03-07 | 2013-03-08 | $67.81 | $200K | -25.0% | -1.8% | -1.8% |
| PLL | SELL | 2013-01-10 | 2013-01-14 | $64.21 | $124K | -25.0% | -1.8% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.